Morgan Stanley downgraded DiaSorin (DSRLF) to Equal Weight from Overweight with a price target of EUR 63, down from EUR 99. The firm says macro headwinds continue to present earnings risk for medical technology services in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSRLF: